Literature DB >> 31882290

Influence of Ethnicity on Clinical Presentation and Quality of Life in Women With Uterine Fibroids: Results From a Prospective Observational Registry.

Ally Murji1, Mohamed Bedaiwy2, Sukhbir Sony Singh3, Olga Bougie4.   

Abstract

OBJECTIVE: This study sought to evaluate ethnic variations in the clinical presentation of women with uterine fibroids.
METHODS: A total of 996 premenopausal women with symptomatic uterine fibroids were enrolled in a prospective, non-interventional, observational registry at 19 clinical sites across Canada (CAPTURE Registry). Patient-reported outcomes were assessed using Uterine Fibroid Symptom and Health-Related Quality of Life Symptom Severity questionnaires and the Aberdeen Menorrhagia Severity Scale (Ruta score). Linear and logistic regression models, adjusted for patient and fibroid characteristics, were used to examine differences among ethnicities for continuous and binary outcomes of interest.
RESULTS: Black women were 4.9 years younger (P < 0.001), were more likely to be nulligravid (P = 0.046), had a 41% longer duration of symptoms before enrolment (P = 0.01), had a 49% larger fibroid volume (P = 0.01), and were more likely to be anemic (P < 0.001) compared with White women. Black women reported lower health-related quality of life scores (-5.19 points; 95% CI -9.90 to -0.48, P = 0.03) compared with White women. East Asian women were 2.0 years younger (P = 0.01), were more likely to be nulligravid (P < 0.001), had a 53% longer duration of symptoms (P = 0.01), had 67% larger fibroid volume (P = 0.01), and were more likely to be anemic (P = 0.003) compared with White women. East Asian women had lower symptom severity scores (-5.95 points; 95% CI -11.16 to -0.75, P = 0.02). Non-White women preferred uterine-preserving treatment options (P < 0.001).
CONCLUSION: Black and East Asian women have an increased burden of disease compared with White women and prefer uterine preservation. There is a discrepancy between disease burden and patient-reported outcomes that may reflect ethnocultural differences in disease experience.
Copyright © 2019 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  factors; leiomyoma; quality of life; race

Mesh:

Year:  2019        PMID: 31882290     DOI: 10.1016/j.jogc.2019.10.031

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  6 in total

1.  Non-hormonal mediators of uterine fibroid growth.

Authors:  Esra Cetin; Ayman Al-Hendy; Michał Ciebiera
Journal:  Curr Opin Obstet Gynecol       Date:  2020-10       Impact factor: 1.927

2.  Quality of ultrasonography reporting and factors associated with selection of imaging modality for uterine fibroids in Canada: results from a prospective cohort registry.

Authors:  Olga Bougie; Mohamed A Bedaiwy; Philippe Laberge; Gerald Lebovic; Nicholas Leyland; Mostafa Atri; Ally Murji
Journal:  CMAJ Open       Date:  2020-08-12

Review 3.  Revisiting the impact of race/ethnicity in endometriosis.

Authors:  Olga Bougie; Ikunna Nwosu; Chelsie Warshafsky
Journal:  Reprod Fertil       Date:  2022-03-17

Review 4.  The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids.

Authors:  Michał Ciebiera; Mohamed Ali; Lillian Prince; Tia Jackson-Bey; Ihor Atabiekov; Stanisław Zgliczyński; Ayman Al-Hendy
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

5.  MiodesinTM Positively Modulates the Immune Response in Endometrial and Vaginal Cells.

Authors:  Carlos Rocha Oliveira; Hudson Polonini; Maria Cristina Marcucci; Rodolfo P Vieira
Journal:  Molecules       Date:  2022-01-25       Impact factor: 4.411

6.  Familial Predisposition to Leiomyomata: Searching for Protective Genetic Factors.

Authors:  Maria V Kuznetsova; Nelly S Sogoyan; Andrew J Donnikov; Dmitry Y Trofimov; Leila V Adamyan; Natalia D Mishina; Jekaterina Shubina; Dmitry V Zelensky; Gennady T Sukhikh
Journal:  Biomedicines       Date:  2022-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.